期刊
NATURE GENETICS
卷 46, 期 5, 页码 487-491出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ng.2955
关键词
-
资金
- Wellcome Trust [098051, WT100183MA, WT088340MA]
- Academy of Medical Sciences
- National Research Council Canada
- EMBO (European Molecular Biology Organization)
- Breakthrough Breast Cancer Research [ICGC 08/09]
- BASIS project
- European Community's Seventh Framework Programme [242006]
The somatic mutations in a cancer genome are the aggregate outcome of one or more mutational processes operative through the lifetime of the individual with cancer(1-3). Each mutational process leaves a characteristic mutational signature determined by the mechanisms of DNA damage and repair that constitute it. A role was recently proposed for the APOBEC family of cytidine deaminases in generating particular genome-wide mutational signatures(1,4) and a signature of localized hypermutation called kataegis1,4. A germline copy number polymorphism involving APOBEC3A and APOBEC3B, which effectively deletes APOBEC3B(5), has been associated with modestly increased risk of breast cancer(6-8). Here we show that breast cancers in carriers of the deletion show more mutations of the putative APOBEC-dependent genome-wide signatures than cancers in non-carriers. The results suggest that the APOBEC3A-APOBEC3B germline deletion allele confers cancer susceptibility through increased activity of APOBEC-dependent mutational processes, although the mechanism by which this increase in activity occurs remains unknown.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据